Figure 3 | Scientific Reports

Figure 3

From: Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States

Figure 3

Risk of tMDS and tAML after RCC by time period of RCC diagnosis. CI confidence interval, RCC renal cell carcinoma, SIR standardized incidence ratio, tMDS treatment-related myelodysplastic syndrome, tAML treatment-related acute myeloid leukemia. ‘tAML’ and ‘tMDS’ inside the figure represents number of patients diagnosed with t-AML or tMDS, in the respective periods.

Back to article page